当前位置：文档库 › 2010 Targeted covalent drugs of the kinase family

2010 Targeted covalent drugs of the kinase family

Available online at https://www.wendangku.net/doc/0516284908.html,

Targeted covalent drugs of the kinase family

Juswinder Singh,Russell C Petter and Arthur F Kluge

In the past decade tremendous progress has been made toward a new class of therapeutics termed ‘targeted covalent drugs’,in which structure-based approaches are employed to create small molecules that inactivate their protein target through targeted covalent attachment to a speci?c cysteine.In the kinase ?eld,this approach is demonstrating promise in overcoming the potency,selectivity,and ef?cacy challenges currently faced by reversible kinase inhibitors,with several advancing into late stage clinical testing.This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR),Her2,and Bruton’s tyrosine kinase (Btk).Here we review recent pre-clinical and clinical advances with targeted covalent kinase inhibitors,and the potential for broader application of the approach.

Address

Avila Therapeutics,100Beaver Street,Waltham,MA,United States Corresponding author:Singh,Juswinder (jsingh@https://www.wendangku.net/doc/0516284908.html, )

Current Opinion in Chemical Biology 2010,14:475–480This review comes from a themed issue on Next Generation Therapeutics

Edited by Michael Gelb and Adrian Whitty Available online 6th July 2010

1367-5931/$–see front matter

Introduction

Recent successes in targeted cancer therapy have made kinase inhibition the preeminent point of intervention in developing novel anti-cancer agents.The persistent chal-lenges in kinase inhibitor drug discovery have been poor selectivity across the family of kinases and the high intracellular concentrations of the endogenous competi-tive substrate,ATP.The principal mechanism to address these challenges has been the design and development of reversible,ATP-competitive inhibitors.Highly targeted covalent,irreversible inhibitors afford an alternative mechanism to overcome these challenges,and inhibitors in this class exhibit distinct pharmacology:remarkable selectivity,prolonged pharmacodynamics relative to exposure,and the potential to overcome resistance mutations by virtue of time-dependent inactivation.Historically,irreversible inhibition has been a proven approach for many classes of drug targets [1,2 ],though most of these covalent drugs were discovered through

serendipity.Despite the ubiquity of drugs that operate by irreversible mechanisms,concerns about potential modi-?cation of off-target proteins have led pharma to avoid this approach [2 ].A new approach to the discovery of targeted irreversible inhibitors using structure-based design has been exempli?ed in the epidermal growth factor receptor (EGFR)family of kinases.This approach,reviewed by Fry in 2000[3],offers an attractive route to a new therapeutic class of kinase inhibitors with potentially superior pro?les and exceptional selectivity.

Over the past decade,the unique bene?ts of targeted,covalent kinase inhibitors have been proven.Speci?cally,covalent inhibitors have demonstrated exceptional potency in overcoming endogenous ATP competition and selectivity that is largely orthogonal to that afforded by conventional,non-covalent inhibitors.In addition,sustained potency in the face of resistance mutations has emerged as an important attribute of this mechanism.To date,?ve irreversible kinase inhibitors have been introduced into clinical study (Figure 1),though taken together the kinases targeted by irreversible inhibitors represent only a small fraction of all kinases targeted by therapeutic agents (Figure 2).This review focuses on their design,progress pre-clinically and clinically,and some thoughts on the path forward.

Informatics as an organizing tool for initiating inhibitor design

This review highlights progress in the design of drugs based on targeting a rare cysteine found in the ATP binding site of EGFR and a few related protein kinases.In the 1990s it was recognized that the potential reactivity of the thiol sidechain of cysteine residues allowed the kinase family of protein drug targets to be organized into subgroups that could be selectively targeted for irrevers-ible inhibition by covalent modi?cation [4].A seminal proof-of-concept experiment showed that thioadenosine covalently inactivated EGFR by forming a disul?de bond with Cys797.This study demonstrated that a particular kinase suitable for targeted covalent inhibition could be identi?ed by informatics,and that a speci?c,covalent inhibitor could be designed by modeling an electrophilic group based upon the binding mode of an existing revers-ible inhibitor.Subsequent alignment of all the kinases in the human genome [5]and systematic matching of their structural domains led to the identi?cation of 10kinases that share a cysteine that structurally corresponds to Cys797in EGFR (Figure 3).In the intervening years since the original proof-of-concept ?nding,there has been explosive growth in the number of x-ray structures for kinases,including EGFR,and the small molecules that

https://www.wendangku.net/doc/0516284908.html,

Current Opinion in Chemical Biology 2010,14:475–480

reversibly bind to them [6],thus greatly expanding the opportunities for design of targeted covalent inhibitors.

Mechanism-based and structure-based design of ErbB family kinase inhibitors

The key design process is to identify that portion of a high-af?nity ligand that is proximal to the targeted cysteine and install electrophilic functionality at that position with geometry that is compatible with the for-mation of the critical bond.In a re?nement of this approach,a general base is included at an adjacent site on the inhibitor to accelerate bond formation by activat-ing the reacting Cys [7](Figure 4).Re?nements in the linker that position the warhead near the cysteine thiol,and modi?cations in the original scaffold itself,can also play a key role in optimizing selectivity and target inac-tivation rate.Irreversible inhibitors that emerge from such an optimization program are rapid inactivators of the targeted kinase,but exhibit remarkable selectivity,both with respect to other kinases and other proteins more generally.

Several 4-anilinoquinazolines,a common scaffold in reversible EGFR inhibitors,have been transformed into irreversible inhibitors by substitution with acrylamide as the electrophilic warhead.These compounds exhibit low reactivity with DTT in enzyme assays and with gluta-thione in cellular assays,showing that their reactivity toward nonspeci?c thiols is low.Successful modi?cation of the target kinase required proper positioning of the warhead relative to the target cysteine,in that congeners bearing an acrylamide in a less-than-optimal geometry

476Next Generation Therapeutics

Figure

Cys-targeted covalent kinase inactivators in clinical development.

Current Opinion in Chemical Biology 2010,14:475–480

https://www.wendangku.net/doc/0516284908.html,

were poor inactivators.Most compelling was the demon-stration that these irreversible inhibitors outperformed their reversible counterparts in tumor growth inhibition in vitro and in animal models [8–10].This was a con-sequence of the covalent drug achieving more complete inhibition of EGFR signaling and more durable inhibition of the target once silenced since return of activity was dependent upon protein resynthesis.The generalizability of this approach toward EGFR and Her2was demon-strated using an irreversible inhibitor based on a thieno-pyrimidine scaffold with a tunable acetylenic warhead that demonstrated superior ef?cacy in a xenograft model compared to the reversible inhibitor,lapatinib [11].Several heterocyclic scaffold –warhead combinations were explored by teams within Parke-Davis,Wyeth,Boehrin-ger-Ingelheim,and others,in the search for drug-like leads of the ErbB family of kinases as potential candidates for cancer therapy [3].Ultimately,in each case,an acryl-amide or a substituted acrylamide proved to be the war-head of choice for imparting potency against the enzyme and in cells,and in obtaining good in vivo activity.Five

clinical candidates have emerged from optimization of leads generated from the application of a modular design paradigm:the 4-anilinoquinazoline series yielded CI-1033[12]and BIBW2992[13]and the 4-anilino-3-cyano-quinoline series yielded neratinib and pelitinib [14].The structure of PF-00299804,also an irreversible ErbB inhibitor,has not been disclosed.

Clinical progress for ErbB-targeted covalent drugs

A ?rst generation of Erb

B family targeted drugs,in-cluding the reversible inhibitors (ge?tinib,erlotinib,and lapatinib)and monoclonal antibodies (e.g.,cetux-imab and trastuzumab)has been shown to produce therapeutic bene?t against a variety of cancers.These drugs address the overexpression of EGFR and Her2,as well as activating somatic mutations that drive increased signaling by ErbB family proteins in many cancers.However,their effectiveness has been blunted by issues such as a signi?cant number of non-responding patients and a decreasing response-rate during drug treatment [15,16].

Targeted covalent drugs of the kinase family Petter,Kluge and Singh 477

Figure

A schematic representation of the human kinome family members:(a)Those family members currently being targeted in clinical trials with reversible,small-molecule inhibitors (data taken from https://www.wendangku.net/doc/0516284908.html,/chembl ).(b)The three targets currently being pursued clinically using irreversible covalent inhibitors,which represents a small fraction of the total drug target space.

https://www.wendangku.net/doc/0516284908.html,

Current Opinion in Chemical Biology 2010,14:475–480

With three irreversible inhibitors in late-stage clinical testing there is optimism about the ?rst approval for a targeted covalent drug [17 ].Neratinib is an irreversible,dual EGFR/Her2inhibitor that,like the approved revers-ible drug lapatinib,targets the inactive conformation of the kinase.Recently,results from a Phase 2trial com-posed of breast cancer patients with tumors positive for ErbB-2,who either had or had not undergone previous trastuzumab therapy,showed neratinib had substantial clinical activity and was well tolerated.The objective response rates were 24%among patients with prior tras-tuzumab treatment and 56%in the trastuzumab-na?

¨ve cohort.P?zer has recently announced advancement of neratinib to Phase 3trials for metastatic breast cancer [18–20].

Two irreversible inhibitors,BIBW2992and PF-00299804,which are dual inhibitors of EGFR and Her2,are in pivotal Phase 3trials for non-small cell lung cancer (NSCLC)

[13,21].A major challenge for the treatment of NSCLC patients,some of whom achieve dramatic responses to the reversible EGFR inhibitors erlotinib/ge?tinib,is the de-velopment of drug resistance.In approximately 50%of patients who relapse there is evidence of resistance due to mutation at T790M in the kinase binding site [15,16].Initially,it had been assumed that T790M resistance was due to loss of af?nity of the drug to the kinase binding site,however x-ray crystallography studies show that the drugs can adopt similar binding modes and have relatively modest differences in af?nity to the T790M form of the protein and to WT [22].It appears that the basis for resistance in cells is due to an increased af?nity for ATP to the T790M mutant form of the enzyme making it more dif?cult for a reversible drug to compete with the mM-levels of intracellular ATP [23 ].

The irreversible inhibitors BIBW2992and PF-00299804retain some activity against the T790M mutant of EGFR.This is probably a consequence of time-dependent inac-tivation,wherein covalency overcomes high competing concentrations of ATP,enabling silencing of the drug target given suf?cient residence time on the mutant protein [24].Detailed cellular pro?ling in 98cell lines of 11irreversible inhibitors,including BIBW2922,along with 10reversible inhibitors showed relatively modest activity against the T790M mutation [25 ].It remains to be seen if effective inhibition of T790M mutant protein with the inhibitors BIBW2992and PF-00299804can be achieved at clinical doses that do not lead to unaccep-table toxicities mediated by inhibition of wild-type EGFR.

Recently,a novel chemotype,an acrylamide-substituted 2,4-dianilino-5-chloropyrimidine,has been reported that shows potent inhibition of T790M mutant EGFR [26 ].Interestingly,this lead has only modest activity against wild-type EGFR.This mutant-selective pro?le may turn out to be useful in a clinical setting to enable a greater therapeutic window in inhibiting mutant EGFR while minimizing toxicities mediated by the inhibition of wt-EGFR [27,28].

478Next Generation Therapeutics

Figure

Ten kinases unified by sequence alignment of cysteine in EGFR.

Figure

Selective formation of the key covalent bond with Cys797on EGFR.Current Opinion in Chemical Biology 2010,14:475–480

https://www.wendangku.net/doc/0516284908.html,

Btk as a drug target for targeted covalent inhibition

Targeted covalent inhibition has also been applied to Bruton’s tyrosine kinase(Btk),an enzyme that infor-matics has identi?ed to contain a Cys at a structurally equivalent position to that seen in EGFR.Exciting pre-clinical and emerging clinical data with an irreversible small-molecule inhibitor support the covalent approach.

Btk is expressed in B-cells and is critically involved in their proliferation,development,differentiation,and sur-vival.Btk represents an exciting target for discovery of drugs modulating the B-cell receptor(BCR)pathway [29,30].Its role in the autoimmune disease X-linked agammaglobulinemia(XLA)has been traced to a mutation in the human Btk.The prominent role of Btk in the BCR signaling pathway and its highly restricted expression pattern makes Btk an attractive drug target for B-cell lymphomas and leukemias.Btk has been reported to be highly phosphorylated in follicular lymphoma patient cells compared to non-malignant B-cells from patients[31].The activated B-cell(ABC)subset of dif-fuse large B-cell lymphoma(DLBCL),which is associ-ated with the lowest5-year survival rate(30%),expresses genes normally induced in human peripheral B-cells after BCR stimulation and has a gene expression pro?le suggesting these cells are in a chronically activated BCR state[32].Recently,the importance of Btk for survival of the activated B-cell-like subset of DLBCL has been reported[33 ].

Historically it has been dif?cult to design selective inhibi-tors of Btk;however,recently there has been substantial pre-clinical and clinical progress in de?ning selective compounds that irreversibly inhibit Btk.The covalent inhibitor PCI-32765(Figure1)has recently entered clinical development and was identi?ed through a struc-ture-based design program similar to that used for inhibi-tors of the ErbB family targets.Beginning with a reversible1-cyclopentyl-4-aminopyrazolo[3,4-d]pyrimi-dine core structure with a diphenyl ether that imparted good activity against Btk and the Src-family kinases,the cyclopentyl was replaced by3-piperidyl,which was then substituted with an acrylamide warhead for bonding to the target cysteine in Btk[34].In addition,a series of2,4-dianilinopyrimidine-based irreversible inhibitors have been developed that exhibit potent activity against the Btk enzyme[35].Enzyme and cellular data for two of these,AVL-101and AVL-291,were presented at the Annual Meeting of the AACR in April,2009. Preliminary evidence of clinical activity was recently reported for PCI-32765in selected patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma in a Phase 1b study(51st meeting of the American Society of Hema-tology,2009).A‘covalent probe’was used to quantify occupancy of the target,Btk,and thereby correlate phar-macodynamics(PD)of Btk inhibition with administered dose.The covalent probe assay uses a?uorescently tagged probe derived from PCI-32765that can covalently bond to any Btk in the sample not already bonded to a molecule of the drug candidate.This probe was added to peripheral blood mononuclear cell(PBMC)lysates from clinical trial subjects,ex vivo.PD studies showed the average drug occupancy of Btk in patient PBMCs was 89%at4h post-dose and77%at24h post-dose.Ex vivo stimulation assays showed near complete functional inhi-bition of the Btk responsive Fc e receptor signaling path-way in basophils and substantial inhibition of the BCR pathway.The ability to correlate target occupancy with dosing in humans represents a powerful aspect to the targeted covalent inhibitor approach and should enable a rational approach to de?ning a suitable dose in patients. Conclusions

The current clinical progress with targeted covalent kinase inhibitors underlines their promise as novel thera-pies.We expect that ongoing clinical success with the current targeted covalent inhibitors will stimulate interest in broader application of the approach.Despite the major effort on kinase inhibitor drug discovery in the pharma-ceutical industry,the primary focus has been on revers-ible non-covalent inhibition.Given the challenges in achieving potency and selectivity across the family,the adoption of alternative mechanisms of action for inhibi-tors is warranted and the data provided in this review support the bene?ts of targeted covalent inhibition.To date,approximately10%of the human kinome has been targeted with inhibitors in clinical development,almost all of which are reversible inhibitors.An analysis of protein kinases suggests that approximately20%may be amenable to a Cys-based targeting approach[36]. We expect this to be an active and growing area of drug discovery and development.

References and recommended reading

Papers of particular interest,published within the period of review, have been highlighted as:

of special interest

of outstanding interest

1.Robertson JG:Mechanistic basis of enzyme-targeted drugs.

Biochemistry2005,44:5561-5571.

Potashman MH,Duggan ME:Covalent modi?ers:an orthogonal approach to drug design.J Med Chem2009,52:1231-1246. Excellent historical perspective on the prevalence of covalent drugs. 3.Fry DW:Site-directed irreversible inhibitors of the ErbB family

of receptor tyrosine kinases as novel chemotherapeutic

agents for cancer.Anti-Cancer Drug Des2000,15:3-16.

4.Singh J,Dobrusin EM,Fry DW,Haske T,Whitty A,McNamara DJ:

Structure-based design of a potent,selective,and irreversible inhibitor of the catalytic domain of the ErbB receptor

subfamily of protein tyrosine kinases.J Med Chem1997,

40:1130-1135.

5.Manning G,Whyte DB,Martinez R,Hunter T,Sudarsanam S:The

protein kinase complement of the human genome.Science

2002,298:1912-1916.

Targeted covalent drugs of the kinase family Petter,Kluge and Singh479 https://www.wendangku.net/doc/0516284908.html, Current Opinion in Chemical Biology2010,14:475–480

6.Kumar K,Petri ET,Halmos B,Boggon TJ:Structure and clinical

relevance of the epidermal growth factor receptor in human cancer.J Clin Oncol2008,26:1742-1751.

7.Wissner A,Overbeek E,Reich MF,Floyd MB,Johnson BD,

Mamuya N,Rosfjord EC,Discafani C,Davis R,Shi X et al.:

Synthesis and structure-activity relationships of6,7-

disubstituted4-anilinoquinoline-3-carbonitriles.The design of an orally active,irreversible inhibitor of the tyrosine kinase

activity of the epidermal growth factor receptor(EGFR)and

the human epidermal growth factor receptor-2(HER-2).J Med Chem2003,46:49-63.

8.Fry DW,Bridges AJ,Denny WA,Doherty A,Gries KD,Hicks JL,

Hook KE,Keller PR,Leopold WR,Loo JA et al.:Speci?c,

irreversible inactivation of the epidermal growth factor

receptor and ErbB2,by a new class of tyrosine kinase

inhibitor.Proc Natl Acad Sci U S A1998,95:12022-12027.

9.Denny WA:The4-anilinoquinazoline class of inhibitors of the

ErbB family of receptor tyrosine kinases.Il Farmaco2001,

56:51-56.

10.Waterson AG,Petrov KG,Hornberger KR,Hubbard RD,

Sammond DM,Smith SC,Dickson HD,Caferro TR,Hinkle KW,

Stevens KL et al.:Synthesis and evaluation of aniline

headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2

kinase inhibitors.Bioorg Med Chem Lett2009,19:1332-1336. 11.Wood ER,Shewchuck LM,Ellis B,Brignola P,Bradshear RL,

Caffero TR,Dickerson SH,Dickson HD,Donaldson KH,Gaul M

et al.:6-Ethynylthieno[3,2-d]-and6-ethynylthieno[2,3-

d]pyrimidin-4-anilines as tunable covalent modi?ers of ErbB kinases.Proc Natl Acad Sci U S A2008,105:2773-2778.

A good example of an effective irreversible inhibitor produced through tuning of the electrophile.Also another example of acceleration of covalent modi?cation of a target cysteine by a general base mounted on the warhead.

12.McIntyre JA,Castaner J,Leeson PA:Canertinib dihydrochloride.

Drugs Future2005,30:771-779.

13.Minkovsky N,Berezov A:BIBW-2992,a dual receptor tyrosine

kinase inhibitor for the treatment of solid tumors.Curr Opin

Invest Drugs2008,9:1336-1346.

14.Boschelli D:4-Anilino-3-quinolinecarbonitriles:an emerging

class of kinase inhibitors.Curr Top Med Chem2002,2:1051-1063.

15.Pao W,Miller VA,Politi KA,Riely GJ,Somwar R,Zakowski MF,

Kris MG,Varmus H:Acquired resistance of lung

adenocarcinomas to ge?tinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med2005, 2:1-11.

16.Kobayashi S,Boggon TJ,Dayaram T,Jeanne PA,Kocher O,

Meyerson M,Johnson BE,Eck MJ,Tenen DG,Halmos B:EGFR mutation and resistance of non-small-cell lung cancer to

ge?tinib.N Engl J Med2005,352:786-792.

17. Ocana A,Emir A:Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer:current status and future directions.Cancer Treat Rev2009,35:685-691.

A review of the early results obtained from clinical testing of irreversible inhibitors of Erb

B TKs and a good discussion of the various mechanisms that have been linked to Her2resistance.

18.Bose P,Ozer H:Neratinib:an oral,irreversible dual EGFR/Her2

inhibitor for breast and non-small cell lung cancer.Expert Opin Invest Drugs2009,18:1735-1751.

19.Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,

Shapiro GI,Jeanne PA,Eder JP,Naughton MJ,Ellis MJ et al.:A phase I study with neratinib(HKI-272),an irreversible pan ErbB receptor tyrosine kinase inhibitor,in patients with solid

tumors.Clin Cancer Res2009,15:2552-2558.

20.Burstein HJ,Sun Y,Dirix LY,Jiang Z,Paridaens R,Tan AR,

Awada A,Ranade A,Jiao S,Schwartz G et al.:Neratinib:an

irreversible ErbB receptor tyrosine kinase inhibitor,in patients with advanced ErbB2-positive breast cancer.J Clin Oncol

2010,28:1301-1307.

21.Gonzales AJ,Hook KE,Althaus IW,Ellis PA,Trachet E,

Delaney AM,Harvey PJ,Ellis TA,Amato DM,Nelson JM et al.:

Antitumor activity and pharmacokinetic properties of

PF-00299804,a second-generation irreversible pan-ErbB

receptor tyrosine kinase inhibitor.Mol Cancer Res2008,

7:1880-1889.

22.Eck MJ,Yun C-H:Structural and mechanistic underpinnings of

the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.Biochim Biophys Acta2010,1804:559-566.

23.

Yun C-H,Mengwasser KE,Toms AV,Woo MS,Greulich H,

Wong K-K,Meyerson M,Eck MJ:The T790M mutation in EGFR kinase causes drug resistance by increasing the af?nity for

ATP.Proc Natl Acad Sci U S A2008,105:2070-2075.

A good presentation of x-ray results with bound inhibitor.

24.Carter TA,Wodicka LM,Shah NP,Velasco AM,Fabian MA,

Treiber DK,Milanov ZV,Atteridge CE,Biggs WH III,Edeen PT et al.: Inhibition of drug-resistant mutants of ABL,KIT,and EGF

receptor kinases.Proc Natl Acad Sci U S A2005,102:11011-

11016.

25.

Sos ML,Rode HB,Heynck S,Peifer M,Fischer F,Kluter S,

Pawar VG,Reuter C,Heuchmann JM,Weiss J et al.:

Chemogenomic pro?ling provides insights into the limited

activity of irreversible EGFR inhibitors in tumor cells

expressing the T790M EGFR resistance mutation.Cancer Res 2010,70:868-874.

This data set is a rich source of SAR information that allows one to compare and contrast results obtained with a focused library of ErbB family kinase inhibitors including the clinical standards lapatinib,erlotinib, and the irreversible inhibitor BIBW2992.

26.

Zhou W,Ercan D,Chen L,Yun C-H,Li D,Capelletti M,Cortot AB, Chirieac L,Iacob RE,Padera R et al.:Novel mutant-selective

EGFR kinase inhibitors against EGFR T790M.Nature2009,

462:1070-1074.

Pyrimidine-based inhibitors bind to the active conformation of kinase and are30–100fold more active against acquired drug-resistance mutant and 100-fold less active against wild-type EGFR.

27.Ercan D,Zejnullahu K,Yonesaka K,Xiao Y,Capelletti M,Rogers A,

Lifshits E,Brown A,Lee C,Christensen JG et al.:Ampli?cation of Egfr T790M causes resistance to an irreversible EGFR

inhibitor.Oncogene2010,29:2346-2356.

28.Baselga J:Is there a role for the irreversible epidermal growth

factor receptor inhibitor EKB-569in the treatment of cancer?

A mutation-driven question.J Clin Oncol2008,24:2225-2226.

29.Uckun FM,Tibbles HE,Vassilev AO:Bruton’s tyrosine kinase as

a new therapeutic target.Anticancer Agents Med Chem2007,

7:624-632.

30.Lindvall J,Blomberg KEM,Vaeliaho J,Vargas L,Heinonen JE,

Bergloef A,Mohamed AJ,Nore BF,Vihinen M,Smith CIE:

Bruton’s tyrosine kinase:cell biology,sequence conservation, mutation spectrum,siRNA modi?cations,and expression

pro?ling.Immunol Rev2005,203:200-215.

31.Irish JM,Czerwinski DK,Nolan GP,Levy R:Altered B-cell

receptor signaling kinetics distinguish human follicular

lymphoma B cells from tumor-in?ltrating nonmalignant B

cells.Blood2006,108:3135-3142.

32.Staudt LM,Dave S:The biology of human lymphoid

malignancies revealed by gene expression pro?ling.Adv

Immunol2005,87:163-208.

33.

Davis RE,Ngo VN,Lenz G,Tolar P,Young RM,Romesser PB,

Kohlhammer H,Lamy L,Zhao H,Yang Y et al.:Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Nature2010,463:88-92.

This paper shows shRNA knockdown of Btk or inhibition by small molecules reduces proliferation of the activated B-cell-like subtype of diffuse large B-cell lymphoma.

34.Pan Z,Scheerens H,Li S-J,Schultz BE,Sprengeler PA,Burrill LC,

Mendonca RV,Sweeney MD,Scott KCK,Grothaus PG et al.:

Discovery of selective irreversible inhibitors for Bruton’s

tyrosine kinase.ChemMedChem2007,2:58-61.

First reported example of a covalent inhibitor of Btk.

35.WO2009/158571.

36.Cohen MS,Zhang C,Shokat KM,Taunton J:Structural

bioinformatics-based design of selective,irreversible kinase inhibitors.Science2005,308:1318-1321.

480Next Generation Therapeutics

Current Opinion in Chemical Biology2010,14:475–https://www.wendangku.net/doc/0516284908.html,